Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc Q2 FY26 Results — Earnings Call Analysis
Q2 FY26 earnings call: what management said on revenue, margins and capex.
What the Q2 FY26 call signalled
1 of 3 strong
The short version
- Epidiolex: Encouraged by strong first-quarter performance ($250 million; 15% revenue growth, 16% volume growth). - Jazz Pharmaceuticals reaffirmed its full year 2026 revenue guidance of $4.25 billion to $4.5 billion, supported by strong Q1 performance and disciplined capital allocation.
From Jazz Pharmaceuticals plc's Q2 FY26 earnings-call transcript · updated 29 May 2026.
Revenue & Sales Performance
- Epidiolex: Encouraged by strong first-quarter performance ($250 million; 15% revenue growth, 16% volume growth). Significant long-term growth potential, especially in adult and long-term care settings via focused initiatives, diagnostic tools, and evidence generation studies. Efforts to improve patient persistency through JazzCares program.
- Xywav: Continued momentum with $408 million revenue in Q1 (18% growth), 425 net patient adds, and over 90% commercial payer coverage. 2026 guidance factors in increased competitive dynamics and generics but maintains a strong market position.
- Modeyso: Strong early launch ($41 million in Q1), treating around 500 patients with potential peak of $500 million. First-line treatment approval could notably expand market and treatment duration.
2 more points from Jazz Pharmaceuticals plc's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Jazz Pharmaceuticals plc said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company maintains a strong financial position with $2.9 billion in cash and investments as of Q1 2026, supported by robust operating cash flow ($408 million in Q1).
- This strong cash flow provides significant flexibility to invest in value-driving commercial and R&D programs.
- Strategic investments focus on commercial brands, pipeline advancement, and business development to broaden the portfolio in key areas: sleep, epilepsy, oncology, and other rare diseases.
- The company is actively engaged in business development, targeting licensing deals and M&A opportunities primarily in rare diseases to expand and strengthen current areas.
- Investments include supporting clinical trials, such as Phase III studies for zanidatamab, Modeyso, and others.
2 more points from Jazz Pharmaceuticals plc's call on capex
Create a free account to keep reading this call
Fundraising & Capital Structure
See what Jazz Pharmaceuticals plc said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Jazz Pharmaceuticals plc said on order book & pipeline — free account, 30 seconds.
Continue your research
Others in Pharmaceuticals this season
- Elanco Animal Health Incorporated (Q2 FY26)
Elanco Animal Health Incorporated Q2 FY26 quarterly results analysis. Elanco expects continued momentum with high single-digit to low double-digit growth in U.S
- Axsome Therapeutics, Inc. (Q2 FY26)
Axsome Therapeutics, Inc. Q2 FY26 quarterly results analysis. AUVELITY peak sales updated to at least $8 billion annually, with roughly equal contributions from
- Viatris Inc. (Q2 FY26)
Viatris Inc. Q2 FY26 quarterly results analysis. Viatris aims for 4% organic revenue growth by 2030, starting strong with 3% growth in Q1 2026. Market Cap $18,7
- Royalty Pharma plc (Q2 FY26)
Royalty Pharma plc Q2 FY26 quarterly results analysis. Royalty Pharma expects strong low-volatility top and bottom line growth through 2030 and beyond, driven b
Potential multibaggers · Q2 FY27
This quarter's potential multibaggers
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Jazz Pharmaceuticals plc and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Jazz Pharmaceuticals plc Q2 FY26 results?
- Epidiolex: Encouraged by strong first-quarter performance ($250 million; 15% revenue growth, 16% volume growth). - Jazz Pharmaceuticals reaffirmed its full year 2026 revenue guidance of $4.25 billion to $4.5 billion, supported by strong Q1 performance and disciplined capital allocation.
What is Jazz Pharmaceuticals plc share price analysis?
Jazz Pharmaceuticals plc currently shows a below-average growth signal. The stock trades at a P/E of 1978.4 with a market cap of $14,768. Investors should review the full earnings analysis for detailed insights.
Is Jazz Pharmaceuticals plc planning capital expenditure?
- The company maintains a strong financial position with $2.9 billion in cash and investments as of Q1 2026, supported by robust operating cash flow ($408 million in Q1).
Keep Jazz Pharmaceuticals plc on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.